Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

mesoridazine (SERENTIL (DISCONTINUED))


DRUG AND DIETARY SUPPLEMENT PROFILES

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include Drug and Dietary Supplement Profiles where your selected drug is a secondary subject of discussion.

ziprasidone (GEODON, ZELDOX)
  • We list this drug as a Do Not Use drug because it is no more effective than older drugs for schizophrenia and causes irregular heartbeat.
thioridazine (MELLARIL)
  • We list this drug as a Do Not Use drug because it is more likely to cause irregular heartbeat than related drugs.

WORST PILLS, BEST PILLS NEWSLETTER ARTICLES

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion.

Massive Misprescribing of Inappropriate Drugs to Hospitalized Elderly Patients
September 2008
A nationwide study published in spring 2008 in the Journal of Hospital Medicine showed that nearly half (49 percent) of almost 500,000 hospital patients older than 65 have been prescribed one or more of 92 drugs known to be unnecessarily unsafe for older patients. 10,000 of these patients had four or more of these inappropriate medicines prescribed during their hospitalization. Among the most common categories of adverse drug reactions these inappropriately prescribed drugs can cause are excessive sedation, abnormally low blood pressure and bleeding. We list the 92 drugs in the article and give further details about the kinds of side effects these drugs can cause.
Antipsychotic Drugs and Dementia in the Elderly
February 2006
Clearly, the concern here is that the use of atypical and typical antipsychotic drugs to control the behavior of elderly nursing home residents who are not psychotic could be considered an unlawful chemical restraint.
Outrage: New Study: Wait Seven Years to Use New Drugs
June 2002
A study published in the May 1, 2002 Journal of the American Medical Association (JAMA) has resulted in a major change in the Health Research Group's drug safety policy. The study, in association with physicians from the Harvard Medical School, examined the frequency and timing of the identification of new adverse drug reactions resulting in the addition of a black box warning in the drug's professional product labeling or its outright removal from the market. Three of the authors have close identification with the Health Research Group: its director, Sidney M. Wolfe, and former HRG staffers Drs. Steffi Woolhandler and David Himmelstein. The other co-authors are affiliated with the Harvard Medical School.

ADDITIONAL INFORMATION FROM PUBLIC CITIZEN

Search results below include Additional Information from Public Citizen where your selected drug is a secondary subject of discussion.

Statement at FDA Hearing on Risk Management of Prescription Drugs (HRG Publication #1620)
The single most important risk management strategy the FDA can undertake in the short-term to reduce the publics risk from preventable adverse drug reactions is to go forward as rapidly as possible with regulations that require pharmacists to distribute scientifically accurate, useful written drug information, or Medication Guides, approved by the agency. At the very least, this would provide consumers with a reliable source of information that they can use to protect themselves from preventable injury.